Compare Stocks: HBPCF, MGNX, IFRX, and KROS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBPCF Helix Biopharma	$0.77	$1.33	$0.77 ▼ $1.73	$58.81M	0.11	10 shs	N/A
IFRX InflaRx	$1.58 +1.0%	$1.91	$0.80 ▼ $2.95	$232.11M	2.59	1.06 million shs	395,552 shs
KROS Keros Therapeutics	$11.33 +0.4%	$11.23	$9.69 ▼ $22.55	$224.67M	1.12	303,037 shs	112,410 shs
MGNX MacroGenics	$2.19 -2.7%	$3.87	$1.29 ▼ $5.08	$139.50M	1.2	956,600 shs	2.60 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBPCF Helix Biopharma	0.00%	0.00%	-54.97%	-54.97%	-55.59%
IFRX InflaRx	0.00%	+18.18%	-17.46%	-8.24%	+11.43%
KROS Keros Therapeutics	0.00%	+5.82%	-2.93%	+10.48%	-25.00%
MGNX MacroGenics	0.00%	-30.77%	-39.84%	-43.75%	+22.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBPCF Helix Biopharma	$0.77	$1.33	$0.77 ▼ $1.73	$58.81M	0.11	10 shs	N/A
IFRX InflaRx	$1.58 +1.0%	$1.91	$0.80 ▼ $2.95	$232.11M	2.59	1.06 million shs	395,552 shs
KROS Keros Therapeutics	$11.33 +0.4%	$11.23	$9.69 ▼ $22.55	$224.67M	1.12	303,037 shs	112,410 shs
MGNX MacroGenics	$2.19 -2.7%	$3.87	$1.29 ▼ $5.08	$139.50M	1.2	956,600 shs	2.60 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBPCF Helix Biopharma	0.00%	0.00%	-54.97%	-54.97%	-55.59%
IFRX InflaRx	0.00%	+18.18%	-17.46%	-8.24%	+11.43%
KROS Keros Therapeutics	0.00%	+5.82%	-2.93%	+10.48%	-25.00%
MGNX MacroGenics	0.00%	-30.77%	-39.84%	-43.75%	+22.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HBPCF Helix Biopharma	0.00	N/A	N/A	N/A
IFRX InflaRx	2.67	Moderate Buy	$7.43	371.66% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	80.94% Upside
MGNX MacroGenics	2.33	Hold	$6.33	189.19% Upside

Current Analyst Ratings Breakdown

Latest HBPCF, MGNX, IFRX, and KROS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	MGNX MacroGenics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform ➝ Positive
9/21/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$8.00
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$9.00 ➝ $11.00
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	$0.15 per share	N/A
IFRX InflaRx	$30K	7,736.93	N/A	N/A	$0.65 per share	2.42
KROS Keros Therapeutics	$244.06M	0.92	$4.55 per share	2.49	$15.51 per share	0.73
MGNX MacroGenics	$149.50M	0.93	N/A	N/A	$0.88 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HBPCF Helix Biopharma	-$3.73M	-$0.04	N/A	N/A	N/A	N/A	-21.61%	-17.14%	10/29/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest HBPCF, MGNX, IFRX, and KROS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	MGNX MacroGenics	-$0.10	N/A	N/A	N/A	$39.18 million	N/A
11/9/2026	Q3 2026	IFRX InflaRx	-$0.07	N/A	N/A	N/A	$0.01 million	N/A
11/4/2026	Q3 2026	KROS Keros Therapeutics	-$0.96	N/A	N/A	N/A	$14.76 million	N/A
10/29/2026	N/A	HBPCF Helix Biopharma	-$0.0813	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HBPCF Helix Biopharma	N/A	0.45	0.45
IFRX InflaRx	N/A	8.22	8.22
KROS Keros Therapeutics	N/A	21.96	21.96
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HBPCF Helix Biopharma	N/A
IFRX InflaRx	42.39%
KROS Keros Therapeutics	71.56%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
HBPCF Helix Biopharma	7.60%
IFRX InflaRx	16.30%
KROS Keros Therapeutics	12.60%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HBPCF Helix Biopharma	7	76.38 million	70.57 million	Not Optionable
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
KROS Keros Therapeutics	92	19.83 million	17.33 million	Optionable
MGNX MacroGenics	293	63.70 million	55.04 million	Optionable

HBPCF, MGNX, IFRX, and KROS Headlines

Recent News About These Companies

MacroGenics Reports Encouraging Interim Phase 2 LINNET Data for Lorigerlimab in Clear Cell Gynecologic Cancer

October 26 at 7:31 AM | quiverquant.comQ

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

October 26 at 7:06 AM | globenewswire.com

MacroGenics, Inc. Announces Positive Interim Phase 1 Results For MGC026 And Plans To Initiate Front-Line Combination Study In SCCHN

October 23 at 5:44 PM | marketscreener.comM

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

October 23 at 9:15 AM | globenewswire.com

MacroGenics, Inc. (MGNX) - What Are Investment Firms Thinking About This Stock?

October 22, 2026 | americanbankingnews.com

Six brokers set USD 6.33 target for MacroGenics stock

October 17, 2026 | ad-hoc-news.deA

MacroGenics, Inc. (MGNX) - What Are Brokerages Thinking About This Stock?

October 17, 2026 | marketbeat.com

MacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors

October 16, 2026 | marketscreener.comM

MacroGenics doses first patient in Phase 1 trial of MGC030 ADC

October 16, 2026 | streetinsider.com

MacroGenics stock has October 23 data ahead in 2026

October 15, 2026 | ad-hoc-news.deA

MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors

October 15, 2026 | marketscreener.comM

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

October 15, 2026 | globenewswire.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

October 9, 2026 | zacks.com

MacroGenics insider exercises 8,000 options for MacroGenics stock

October 9, 2026 | ad-hoc-news.deA

MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead

October 7, 2026 | ad-hoc-news.deA

MacroGenics stock faces October data after a Q2 revenue miss

October 5, 2026 | ad-hoc-news.deA

2,488,252 Shares in MacroGenics, Inc. $MGNX Acquired by Bank of America Corp DE

September 26, 2026 | marketbeat.com

MacroGenics stock holds at USD 4.12 as cash strength stands out

September 23, 2026 | ad-hoc-news.deA

MacroGenics stock edges lower as biotech analysts highlight risk and upside

September 19, 2026 | ad-hoc-news.deA

MacroGenics consensus price target rises 12% to $9.52

September 14, 2026 | msn.com

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBPCF, MGNX, IFRX, and KROS Company Descriptions

Helix Biopharma OTCMKTS:HBPCF

$0.77 0.00 (0.00%)

As of 10/23/2026

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

InflaRx NASDAQ:IFRX

$1.58 +0.02 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 06:32 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Keros Therapeutics NASDAQ:KROS

$11.33 +0.05 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$11.34 +0.01 (+0.04%)

As of 04:10 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

MacroGenics NASDAQ:MGNX

$2.19 -0.06 (-2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.05 (+2.24%)

As of 06:13 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HBPCF, MGNX, IFRX, and KROS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HBPCF, MGNX, IFRX, and KROS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HBPCF, MGNX, IFRX, and KROS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBPCF, MGNX, IFRX, and KROS Company Descriptions

Helix Biopharma OTCMKTS:HBPCF

InflaRx NASDAQ:IFRX

Keros Therapeutics NASDAQ:KROS

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HBPCF, MGNX, IFRX, and KROS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HBPCF, MGNX, IFRX, and KROS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HBPCF, MGNX, IFRX, and KROS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBPCF, MGNX, IFRX, and KROS Company Descriptions

Helix Biopharma OTCMKTS:HBPCF

InflaRx NASDAQ:IFRX

Keros Therapeutics NASDAQ:KROS

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools